Philadelphia-area biotech LIV Process develops a patented visualization system that makes otherwise invisible Clostridioides difficile spores visible on healthcare surfaces in real time. Its water-based solution binds to proteins on the spores and fluoresces under a dedicated light, helping hospital environmental-services teams target cleaning and verify that contamination has been removed. Founded by inventor and longtime medical-product executive Michael McIntyre, the company operates from headquarters in Ardmore with research and development in Cambridge.
StetPulseLed by Johns Hopkins biomedical engineering undergraduates, StetPulse makes UV-C Lightboxes that sanitize clinician stethoscopes in under a minute. Its wall-mountable system is designed for placement outside patient rooms and was validated through a pilot trial at Johns Hopkins Hospital for inactivating COVID-19, MRSA, and C. diff.
Biomeme, IncSince 2012, Biomeme has built its identity around decentralizing molecular diagnostics, developing field-ready testing for people who need biological answers outside a central laboratory. The Philadelphia company works with military and first-responder organizations as well as healthcare and research users, and makes its systems on site in a 40,000-square-foot vertically integrated facility.541714PHILADELPHIA, PA
VyvVyv, founded by CEO and co-founder Colleen Costello after her grandmother contracted MRSA in a hospital, develops UV-free antimicrobial LED lighting that illuminates occupied spaces while continuously reducing microbial growth. Based in Latham, New York, the company combines engineering, microbiology and clinical research to adapt its proprietary visible-spectrum technology for commercial luminaires, transportation and consumer products. Its lights are designed for continuous use around people and have been tested against viruses, bacteria, fungi, yeast and mold.LATHAM, NY
BioSherpa, LLCBioSherpa, LLC develops the BioSherpa Specimen Transport System, a biofilm-reducing diagnostic agent designed to help laboratories culture infectious pathogens even after patients have received antibiotics. The system grew from infectious-disease research conducted by founders Tom Cumbo and Destin Radder in Nepal and Peru, and was later developed with physician and former Army officer Christopher Hutson. Its research includes cases where BioSherpa STS identified pathogens missed by standard collection methods, including a case involving three days of effective antibiotic treatment.LEWISTON, NY